PAR-24-062: Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 16, 2025.
From the official notice on Grants.gov, last changed January 17, 2025. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsOptional
- Funded byNIDA
- Median yearly award$528,957
- Typical project length2 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under PAR-24-062 were run by National Institute on Drug Abuse (NIDA, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-062 in the NIH Guide.
Key dates
| Posted | November 7, 2023 |
|---|---|
| Deadline | January 16, 2025 |
| Archived by Grants.gov | February 15, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to support translational research across epidemiology, services, and prevention research to relieve the burden of substance use on public health. This NOFO solicits applications that start with a planning phase, which if successful will be able to translate rapidly from hypotheses to intervention, or from pilot to implementation, with potential for transformative findings through innovative translational research.
Funded under PAR-24-062 so far
NIH funded 4 projects under PAR-24-062 in fiscal 2024 to 2026, at 3 institutions. The median yearly award was $528,957.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk | Boston Medical Center | 2026 | $1.1 million |
| Clinical Decision Supports to Prevent Teen Substance Use in Pediatric Primary Care | Yale University | 2026 | $527,151 |
| Substance use and HIV Action for Reentry and Engagement | Emory University | 2025 | $487,036 |
| A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk | Boston Medical Center | 2024 | $1.2 million |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Who has won Alcohol Research Programs grants before
From fiscal 2021 to 2025, Alcohol Research Programs (93.273) awarded $2.2 billion across 2,255 grant awards, an average of $974,579 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 75 | $86.5 million |
| University of North Carolina at Chapel Hill | North Carolina | 76 | $60.7 million |
| Trustees of Indiana University | Indiana | 47 | $54.8 million |
| University of California, San Diego | California | 47 | $54.5 million |
| The Medical University of South Carolina | South Carolina | 57 | $45.8 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-062 still open?
No. It closed on January 16, 2025.
Who can apply for Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)?
Closed January 16, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-24-062?
NIH RePORTER lists 4 projects funded under PAR-24-062 in fiscal 2024 to 2026, at 3 institutions. The most were at Boston Medical Center, Yale University, Emory University.
Who has won Alcohol Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, University of North Carolina at Chapel Hill, Trustees of Indiana University. The program made 2,255 awards worth $2.2 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)